FDA approves the augmentation of glucose monitoring for weight loss

The food and medication management approved the first ever the glucose monitoring system specifically for weight management from Startup SignsThe company said on Wednesday, establishing a new option to the Americans to manage their weight.

Current treatment options for weight management – Popular medications like GLP-1S and surgical interventions – are usually limited to patients with obesity or certain BMI. Drugs of obesity such as NEW NORDISKVegs and Eli LillyZepbound can also be difficult to access because of its high costs, limited American insurance insurance and limited offer.

But now, each patient can buy membership in Signo and approaches its system. Uses AI platform and continuous monitor of glucose off, or CGM, from Dexcom To offer personalized, real-time and weather conditions for weight management.

“Now the solution that everyone can help to help travel weight loss and don’t have to be a certain number of pounds to use it for average American,” Sharam Fouladgar-Mercer, in the interview on Tuesday, in an interview on Tuesday. “The average person can have five kilograms to lose or lose 100 pounds. We are here to help them at any time on that path.”

Ecidemy of obesity costs the American health system More than $ 170 billion a yearAccording to the centers for data on disease control and prevention. Nearly 74% of Americans have excessive weight or obese, Government data He says. Signo hopes that it will be able to do “a real big indentation in that curve to improve many of us,” Fouladgar-Mercer said.

Customers signing up for Signo select A three-month or six-month plan currently costs 139 and $ 129, respectively. The company will ship all CGMS patient needs for the number of months in the plan that selects.

The insurers do not currently cover the weight management system, but the plans are approximately $ 1000 in the USA, cooperates with the health insurance company and employers to cover the system, the company is in the statement in the CNBC statement. Signos said he expects “this to develop quickly because the interest rate of weight settled to spread.”

The Signos system can be used in combination with GLP-1S or Bariatric surgery, Fouladgar-Mercer said. Said patients can also use the system after you took off with GLP-1 to maintain their weight

CGMS are small sensors worn on the upper hand that follows the level of glucose, mainly for people with diabetes. This information is sent wirelessly in the Signos application, which also allows patients to schedule their food intake and levels of exercise, between other information and a platform used to recommend.

In addition to helping people, the system aims to help users understand how their bodies respond to specific food and exercise patterns and execute changes in behavior in the long run and maintain their weight.

Signors did not share how many patients currently use their glucose monitoring system, but Fuladgar-Mercer said that tens of thousands of people have already tried over time. He said Signo caught his CGM inventory and software capacity to “treat a fairly massive scale” after approval.